| Bobbi Winn, LPN | |
|
5 Remington Cove, Little Rock, AR 72204 | |
| (501) 850-8788 | |
| (501) 850-8791 |
| Full Name | Bobbi Winn |
|---|---|
| Gender | Female |
| Speciality | Specialist |
| Location | 5 Remington Cove, Little Rock, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174926547 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | L045691 (Arkansas) | Secondary |
| 174400000X | Specialist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Bobbi Winn, LPN 5 Remington Cove, Little Rock, AR 72204 Ph: (501) 850-8788 | Bobbi Winn, LPN 5 Remington Cove, Little Rock, AR 72204 Ph: (501) 850-8788 |
News Archive
OnCallData, whose pioneering electronic-prescribing product was the first electronic prescribing application to launch two-way connectivity with national pharmacy chains, announced this week that it has integrated its systems with ShareStream, a rich media platform that allows organizations to educate and train their workforces through multimedia while safeguarding and controlling access to content during online delivery through digital rights management, to provide online learning and secure, media-based communications within the OnCallData Community Health Portal.
A bacterium that lives in rivers, streams and human aqueducts uses nature's strongest glue to stay in one place. The bacterium could be mass produced and used to coat surfaces for medical and engineering purposes.
The Pharmaceutical Care Management Association (PCMA) released the following statement today on new legislation introduced by Congressman Stephen F. Lynch (D-Mass.) — the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (H.R. 4489) — which would increase prescription drug costs and reduce choices for federal employees
A PhD student at Xi'an Jiaotong-Liverpool University in Suzhou, China is carrying out work that could have a significant impact on drugs developed to prevent and treat migraines.
Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present a large international tumor profiling study of colorectal cancer at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by Caris Molecular Intelligence, this study represents the largest, multi-national analysis in a single laboratory setting of the main molecular anomalies in colorectal cancer.
› Verified 9 days ago